**Global COVID-19 advice for people with MS**

COVID-19 is a new illness that can affect your lungs, airways and other organs. It is caused by a novel coronavirus (called SARS-CoV-2) that has spread around the world.

The advice below was developed by MS clinicians\* and research experts. It is based on the emerging evidence of how COVID-19 affects people with multiple sclerosis (MS) and expert opinion. This advice will be reviewed and updated as further evidence about COVID-19 and SARS-CoV-2 becomes available.

For information about COVID-19 vaccines and MS, please see page 4.

**Advice for people with MS**

Current evidence shows that simply having MS does not make you more likely to develop COVID-19 or to become severely ill or die from the infection than the general population. However, the following groups of people with MS are more susceptible to having a severe case of COVID-19:

* People with progressive MS
* People with MS over the age of 60
* Men with MS
* Black people with MS and possibly South Asian people with MS
* People with higher levels of disability (for example, [an EDSS score](https://www.mssociety.org.uk/about-ms/treatments-and-therapies/getting-treatment-for-ms/expanded-disability-status-scale) of 6 or above, which relates to needing to use a walking stick)
* People with MS and obesity, diabetes or diseases of the heart or lungs
* People taking certain disease modifying therapies for their MS (see below)

All people with MS are advised to follow [World Health Organization](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public) guidelines for reducing the risk of infection with COVID-19. People in the higher risk groups should pay particular attention to these measures. We recommend to:

* Practise social distancing by keeping at least 1.5 metres\*\*\* distance between yourself and others, to reduce your risk of infection when they cough, sneeze or speak. This is particularly important when indoors but applies to being outdoors as well.
* Make wearing a mask a normal part of being around other people and ensure that you are using it correctly by following [these instructions](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks).
* Avoid going to crowded places, especially if indoors and the room is poorly ventilated. Where this is not possible, ensure to wear a mask and practise social distancing.
* Wash your hands frequently with soap and water or an alcohol-based hand rub (70% alcohol content is considered most effective).
* Avoid touching your eyes, nose and mouth unless your hands are clean.
* When coughing and sneezing, cover your mouth and nose with a flexed elbow or tissue.
* Clean and disinfect surfaces frequently especially those which are regularly touched.
* Talk to your healthcare provider about optimal care plans, through video consultations or in-person visits where needed. Visits to health clinics/centres and hospitals should not be avoided if they are recommended based on your current health needs.
* Stay active and try to take part in activities that will enhance your mental health and well-being. Physical exercise and social activities that can take place outside and with social distancing are encouraged.

Caregivers and family members who live with, or regularly visit, a person with MS in one of the higher risk groups should also follow these recommendations to reduce the chance of bringing COVID-19 infection into the home.

**Advice regarding disease modifying therapies for MS**

Many disease modifying therapies (DMTs) for MS work by suppressing or modifying the immune system. Some MS medications might increase the likelihood of developing complications from COVID-19 but this risk needs to be balanced with the risks of stopping or delaying treatment.

We recommend that people with MS currently taking DMTs continue with their treatment, unless advised to stop by their treating clinician.

People who develop symptoms of COVID-19 or test positive for the infection should discuss their MS therapies with their MS care provider or another healthcare professional who is familiar with their care.

Before starting on any new DMT or changing an existing DMT, people with MS should discuss with their healthcare professional which therapy is the best choice for their individual circumstances. This decision should – among other factors - consider the following information:

* MS disease course and activity
* The risks and benefits normally associated with different treatment options
* Additional risks related to COVID-19, such as:
  + The presence of other factors for a more severe case of COVID-19, such as older age, obesity, pre-existing lung or cardiovascular disease, progressive MS, higher risk race/ethnicity etc, as listed above
  + The current and anticipated future COVID-19 risk in the local area
  + Risk of exposure to COVID-19 due to lifestyle, for example whether they are able to self-isolate or are working in a high-risk environment
  + Emerging evidence on the potential interaction between some treatments and COVID-19 severity
  + Previous infection with COVID-19
  + Availability of and access to a COVID-19 vaccine

**Evidence on the impact of DMTs on COVID-19 severity**

Interferons and glatiramer acetate are unlikely to impact negatively on COVID-19 severity. There is some preliminary evidence that interferons may reduce the need for hospitalisation due to COVID-19.

The evidence available suggests that people with MS taking dimethyl fumarate, teriflunomide, fingolimod, siponimod and natalizumab do not have an increased risk of more severe COVID-19 symptoms. It is unlikely that people with MS taking ozanimod will have an increased risk either, as it is assumed to be similar to siponimod and fingolimod.

There is some evidence that therapies that target CD20 – ocrelizumab and rituximab – may be linked to an increased chance of having more severe COVID-19, including a greater risk of hospitalisation. However, these therapies should still be considered as an option for treating MS during the pandemic. People with MS who are taking them (or ofatumumab and ublituximab that work in the same way) should be particularly vigilant regarding the advice above to reduce their risk of infection.

More data on the use of alemtuzumab and cladribine during the COVID-19 pandemic are required to make any assessment of their safety. These treatments reduce lymphocyte counts (lymphocytes are a type of white blood cell that helps protect the body from infection), so people treated with these therapies may be less able to fight infection and should be particularly careful to avoid risk of infection with COVID-19.

Recommendations on delaying second or further doses of alemtuzumab, cladribine, ocrelizumab and rituximab due to the COVID-19 outbreak differ between countries. People who take these medications and are due for the next dose should consult their healthcare professional about the risks and benefits of postponing treatment. People are strongly encouraged not to stop treatment without the advice of their clinician.

**Advice regarding aHSCT**

Autologous Haematopoietic Stem Cell Transplantation (aHSCT) includes intensive chemotherapy treatment. This severely weakens the immune system for a period of time. People who have recently undergone aHSCT should consider extending the period they remain in isolation during the COVID-19 outbreak to at least six months. People who are due to undergo treatment should consider postponing the procedure in consultation with their healthcare professional. If aHSCT is given, chemotherapy should be administered in rooms isolated from other hospital patients.

**Seeking medical advice for relapses and other health concerns**

People with MS should still seek medical advice if they experience changes in their health that may suggest a relapse or another underlying issue such as an infection. This can be done using alternatives to in-person clinic visits (such as telephone or video consultations) if the option is available. In many cases, it is possible to manage relapses at home.

The use of steroids for treating relapses should be carefully considered and only used for relapses that need intervention. There is some evidence that receiving high-dose steroids in the month prior to contracting COVID-19 increases the risk of a more severe infection requiring a visit to hospital. Where possible, the decision should be made with a neurologist experienced in the treatment of MS. People who receive steroid treatment for a relapse should be extra vigilant and may want to consider self-isolation for at least a month to reduce their risk from COVID-19. Note that once someone has been infected with COVID-19, steroids may be used to treat COVID-19, to dampen the excessive immune response often referred to as a ‘cytokine storm’. Note that the steroids and dosages used in this context are different from the situation of a MS relapse.

People with MS should continue to participate in rehabilitation activities and stay active as much as possible during the pandemic. This can be done through remote sessions where available or in clinics/centres as long as people with MS attending the clinics/centres follow safety precautions to protect themselves and limit the spread of COVID-19. People with concerns about their mental health should seek advice from their healthcare professional.

**Flu vaccine**

The flu vaccine is safe and recommended for people with MS. For countries entering flu season, we recommend people with MS receive the seasonal flu vaccine where it is available.

**Advice for children or pregnant women with MS**

At this time there is no specific advice for women with MS who are pregnant. There is general information on COVID-19 and pregnancy from the [World Health Organization](https://www.who.int/reproductivehealth/publications/emergencies/COVID-19-pregnancy-ipc-breastfeeding-infographics/en/). There is no specific advice for children with MS; they should follow the advice above for people with MS.

**COVID-19 vaccines and MS**

In this section, we will review the current vaccine types and discuss vaccination timing and disease modifying therapy administration. Given the seriousness of COVID-19 - which carries a 1-3% mortality risk as well as risk for serious illness and prolonged ill-health for many - we wish to emphasise these key points:

* **All people with MS should be vaccinated against COVID-19[[1]](#footnote-2)**
* **People with MS should be vaccinated as soon as the vaccine is available to them**
* **Even once you have received the vaccine, it is important to continue to take precautions against COVID-19, such as wearing a face mask, social distancing and washing your hands, because new variants are emerging that may not be protected against by the current vaccines.**

There are several COVID-19 vaccines in use in different countries around the world, with new ones being approved regularly. Instead of assessing each vaccine individually, we have provided information below about the main types of COVID-19 vaccines in use and in development. This guidance is based on available information and we will update it as new data become available.

We do not know how many people in the COVID-19 vaccine clinical trials had MS, so data on the safety and effectiveness of COVID-19 vaccines specifically for people with MS are not yet available. Our guidance is therefore based on data from the general population in the vaccine clinical trials, and guided by prior experience regarding vaccination of people with MS.

Vaccines work by using a part of the virus that causes the disease (such as its genetic code or ‘spike protein’), or an inactivated or weakened version of the virus, to prompt a response from the human immune system. In turn, this causes the body to produce antibodies and T-cells (a special population of white blood cells) to fight the virus, preventing it from entering and infecting other cells in the body. These vaccines do not lead to any genetic change in our bodies, will not get into the brain, and would not alter the genetic code of a foetus. There are currently five different types of COVID-19 vaccine in use or in development that work in different ways (with examples below). A useful COVID-19 vaccine tracker can be found at: <https://covid19.trackvaccines.org/>

1. **mRNA vaccines** have the genetic code for the coronavirus ‘spike’ protein made as an “mRNA” (a type of temporary genetic message), which is formulated into tiny fatty droplets for delivery. The mRNA directs production of the spike protein, which is seen and targeted by the immune system (that makes antbodies and T cells).
   * Pfizer-BioNTech (Comirnaty)
   * Moderna (Moderna mRNA)
2. **Non-replicating viral vector vaccines** have the genetic code for the spike protein in a viral vector. These vectors are best understood as just the shell and delivery mechanism of a virus (commonly from an adenovirus), but they lack the parts a virus needs to replicate and so can never cause an infection. Similar to mRNA vaccines, viral vector vaccines direct the production of the spike protein so that it can be seen and targeted by the immune system.
   * AstraZeneca/Oxford (Covishield)
   * Gamaleya Research Institute (Gam-COVID-Vac or Sputnik V)
3. **Inactivated virus vaccines** use an inactivated form of the whole coronavirus. The coronavirus has been ‘killed’ so that it is unable to get into cells and replicate, and it cannot cause a COVID-19 infection. The immune system recognises the whole virus, even though it is inactivated.
   * Sinovac (CoronaVac)
4. **Protein vaccines** have the coronavirus spike protein itself (not the genetic code), along with something that boosts the immune system (an ‘adjuvant’) to ensure the spike protein is targeted.
   * Novavax (NVX-CoV2373)
5. **Live attenuated vaccines** use a weakened, but still replicating virus. Such vaccines work by causing a mild infection in people with regular immune function. **They can be dangerous in a person with a compromised immune system, so would not suitable for many people with MS, due to the way some disease modifying treatments work.**
   * Currently (March 2021), there are no live attenuated COVID-19 vaccines in use – they are only being researched.

**The following guidance refers to the mRNA, non-replicating viral vector, inactivated virus or protein COVID-19 vaccines (types 1-4 listed above).**

**People with MS should get a COVID-19 vaccine**

The science has shown us that the COVID-19 vaccines are safe and effective. Like other medical decisions, the decision to get a vaccine is best made in partnership with your healthcare professional. You should get a COVID-19 vaccine as soon as it becomes available to you. The risks of COVID-19 disease outweigh any potential risks from the vaccine. In addition, members of the same household and close contacts should also get a vaccine as soon as they can to maximise protection against COVID-19.

Most of the COVID-19 vaccines require two doses, and where this is the case, you need to follow your country’s guidelines on the timing of the second dose. Following full vaccination (both doses), it may take up to at least 2 weeks for the vaccination to achieve full effect.

If you have had COVID-19 and recovered, you should also get the vaccine, because prior infection does not appear to protect from future COVID-19 infection indefinitely. It is normal practice to wait until you have recovered from an illness before being vaccinated. But you should still get vaccinated as soon as you can after recovery, following the government guidelines in your country.

We do not know how long a person is protected from COVID-19 after being vaccinated, although clinical trial data indicate that protection is high for at least multiple months. Repeated doses of the COVID-19 vaccines may be required in future, similar to the flu vaccine.

Even once you have received the vaccine, it is important to continue to take precautions against COVID-19, such as wearing a face mask, social distancing, washing your hands and following any local rules about getting tested for COVID-19 when necessary.

**There is no evidence that people with MS are at higher risk of complications from the mRNA, non-replicating viral vector, inactivated virus or protein COVID-19 vaccines (1-4), compared to the general population.**

The mRNA, non-replicating viral vector, inactivated virus or protein COVID-19 vaccines do not contain live viruses and will not cause COVID-19 disease. These types of vaccine are not likely to trigger an MS relapse or to worsen chronic MS symptoms.

However, **people with MS should avoid receiving live attenuated vaccines (5)**. Given that there may be COVID-19 vaccines developed in the future that use this technology, it is important to know which COVID-19 vaccine you are offered.

You do not need to self-isolate after the vaccination. The vaccines can cause side effects, including fever or fatigue, which should not last more than a few days after vaccination. A fever can make your MS symptoms worse temporarily, but they should return to previous levels after the fever is gone. Even if you have side effects from the first dose, it is important to get the second dose of the vaccine (for vaccines requiring two doses) for it to be fully effective. Having side effects, such as fever, muscle discomfort and fatigue are a sign that the vaccine is doing its job (it is getting your body to mount a response against the virus, and therefore is starting to protect you).

**The COVID-19 vaccines can be administered to people with MS who are being treated with MS therapies**

Continue taking your disease modifying therapy (DMT) unless you are advised by your MS healthcare professional to stop or delay it. Stopping some DMTs abruptly can cause severe worsening of MS.

* **It is safe to receive a COVID-19 vaccine when you are on MS therapies (DMTs)**
* **Delaying the start of a DMT, or altering DMT timing, is not a safety issue - it is a strategy to allow the vaccine to be fully effective**

Some DMTs may make the vaccine less effective because the DMT has reduced your ability to mount an immune response. However, you are still able to respond to the vaccine to some extent, and will still have a reduced risk of severe COVID-19 disease after vaccination. Given the potential serious health consequences of COVID-19 disease, getting the vaccine when it becomes available to you may be more important than optimally timing the vaccine with your DMT.

If you are able to plan when you receive your vaccine, please discuss with your MS healthcare provider how and whether to coordinate the timing of your vaccine with the timing of your DMT dose - if you are on a DMT where this is relevant (see below). This should help ensure the vaccine is still effective at generating antibodies to the coronavirus.

The decision of when to get the COVID-19 vaccine should include an evaluation of your risk of COVID-19, (see the list near the beginning of this advice on groups who are more at risk), and the current state of your MS. Work with your MS healthcare provider to determine the best schedule for you. If the risk of your MS worsening outweighs your risk of COVID-19, do not alter your DMT schedule and get the vaccine when it is available to you. If your MS is stable, consider the following adjustments in the administration of your DMT to enhance the effectiveness of the vaccine:

**Interferons, glatiramer acetate, teriflunomide, monomethyl fumarate, dimethyl fumarate, diroximel fumarate, natalizumab —** If you are about to start one of these DMTs for the first time, do not delay starting it for your COVID-19 vaccine injection.If you are already taking one of these DMTs, no adjustments to your DMT administration are needed.

**Fingolimod, siponimod, ozanimod** — If you are about to start fingolimod, siponimod or ozanimod, consider getting the COVID-19 vaccine so that the second vaccine injection is done two to four weeks before starting fingolimod, siponimod or ozanimod. If you are already taking fingolimod, siponimod or ozanimod, continue taking it as prescribed and get vaccinated as soon as the vaccine is available to you.

**Alemtuzumab, cladribine** — If you are about to start alemtuzumab or cladribine, consider getting the COVID-19 vaccine so that the second vaccine injection is done at least four weeks before starting alemtuzumab or cladribine. If you are already taking alemtuzumab or cladribine, consider starting the vaccine injections at least 12 weeks after the last alemtuzumab or cladribine dose. When possible, resume alemtuzumab or cladribine at least four weeks after the second vaccine injection. ***This suggested scheduling is not always possible and getting the vaccine when it becomes available to you may be more important than timing the vaccine with your DMT. Work with your MS healthcare provider to determine the best schedule for you.***

**Ocrelizumab, rituximab —** If you are about to start ocrelizumab or rituximab, consider getting the COVID-19 vaccine so that the second vaccine injection is two to four weeks before starting ocrelizumab or rituximab. If you are already taking ocrelizumab or rituximab, consider getting the vaccine injections at least 12 weeks after the last DMT dose. When possible, resume ocrelizumab or rituximab at least 4 weeks after the second vaccine injection. ***This suggested scheduling is not always possible and getting the vaccine when it becomes available to you may be more important than timing the vaccine with your DMT. Work with your MS healthcare provider to determine the best schedule for you.***

**Ofatumumab—**If you are about to start this DMT, consider getting the COVID-19 vaccine so that the second vaccine injection is two to four weeks before starting your DMT. If you are already taking ofatumumab, consider getting the vaccine injections four weeks after your last ofatumumab injection. When possible, resume ofatumumab injections at least four weeks after the second vaccine injection. ***This suggested scheduling is not always possible and getting the vaccine when it becomes available to you may be more important than timing the vaccine with your DMT. Work with your MS healthcare provider to determine the best schedule for you.***

**High-dose steroids —** Consider getting the vaccine injections three to five days after the last dose of steroids.

**All of us have a personal responsibility to slow the spread of the pandemic and eliminate the virus as quickly as possible**

The authorisations of safe and effective vaccines for COVID-19 bring us one step closer to eliminating this virus. In areas where there is ongoing local transmission of COVID-19, in addition to getting vaccinated, you should refer to your local guidelines about transmission mitigation strategies, which are likely to include wearing a face mask, social distancing and washing your hands.

*This statement was first agreed on 13 March 2020. The latest revisions were agreed and published on 5 March 2021.*

The individuals listed below were consulted in the development of this advice. The guidance relating to the COVID-19 vaccines was developed in conjunction with the [National MS Society working group](https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance#section-6).

\***MS neurologists and scientific specialists**

Professor Alfredo Rodriguez Antiguedad – Universidad del País Vasco, Spain

Professor Brenda Banwell, Chair of MSIF’s International Medical and Scientific Advisory Board (IMSB) – University of Pennsylvania, USA

Professor Amit Bar-Or - University of Pennsylvania, USA

Professor Simon Broadley – Griffith University and Gold Coast Hospital, Queensland, Australia

Professor Olga Ciccarelli – Institute of Neurology, UCL, UK

Professor Maria Pia Amato, President of ECTRIMS – University of Florence, Italy

Professor Andrew Chan – Bern University Hospital, Switzerland

Professor Jeffrey Cohen, President of ACTRIMS – Cleveland Clinic Mellen Center for MS, USA

Professor Jorge Correale, Deputy Chair of MSIF’s IMSB – FLENI, Argentina

Professor Giancarlo Comi – IRCCS Ospedale San Raffaele, Italy

Dr Huang Dehui – Chinese PLA General Hospital, China

Vanessa Fanning – Australia

Professor Kazuo Fujihara, President of PACTRIMS – Fukushima Medical University School of Medicine, Japan

Professor Gavin Giovannoni – Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK

Professor Fernando Hamuy Diaz de Bedoya, President of LACTRIMS – Universidad Nacional de Asuncion, Paraguay

Professor Bernhard Hemmer – Technische Universität München, Germany

Professor Joep Killestein – Amsterdam UMC, Netherlands

Professor Barbara Kornek – Medical University Vienna, Austria

Professor Daphne Kos, President of RIMS – KU Leuven, National MS Center Melsbroek, Belgium

Dr Céline Louapre – Sorbonne Université, France

Professor Catherine Lubetzki – ICM, France

Professor Aaron Miller, Chairman, National Medical Advisory Committee, National MS Society (US) – Icahn School of Medicine at Mount Sinai, USA

Anne Restan – Ireland

Professor Mohammad Ali Sahraian – MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Iran

Professor Marco Salvetti – Sapienza University, Italy

Professor Nancy Sicotte - Cedars-Sinai Medical Center, USA

Dr Joost Smolders – ErasmusMC, Netherlands

Professor Per Soelberg Sørensen – University of Copenhagen, Denmark

Professor Maria-Pia Sormani, on behalf of the Italian MuSC-19 study – University of Genoa, Italy

Ana Torredemer – Spain

Professor David Tscharke – Australian National University, Australia

Professor Bassem Yamout, President of MENACTRIMS – American University of Beirut Medical Center, Lebanon

Professor Frauke Zipp – Johannes Gutenberg University Medical Center in Mainz, Germany

\*\***MSIF and its member organisations**

Dr Anne Helme, Nick Rijke, Victoria Gilbert, Peer Baneke – MS International Federation

Phillip Anderson – MS Society (UK)

Pedro Carrascal – Esclerosis Múltiple España (Spain)

Dr Tim Coetzee, Dr Doug Landsman, Julie Fiol – National MS Society (US)

Professor Judith Haas – Deutsche Multiple Sklerose Gesellschaft Bundesverband e.V (Germany)

Dr Kirstin Heutinck – Stichting MS Research (Netherlands)

Dr Pam Kanellis – MS Society of Canada

Elisabeth Kasilingam – European MS Platform

Dr Marc Lutz – La Société suisse de la sclérose en plaques (Switzerland)

Marie Lynning – Scleroseforeningen (Denmark)

Dr Julia Morahan – MS Research Australia

Dr Emmanuelle Plassart-Schiess – ARSEP Fondation (France)

Dr Paola Zaratin – Associazione Italiana Sclerosi Multipla Onlus (Italy)

With thanks to Dr Clare Walton and Kathleen Costello for their input to earlier versions of this guidance.

\*\*\* National and international guidelines on physical distancing vary between at least one metre and two metres. People should consider their national guidance and be aware that these are minimum distances, longer being better.

1. Provided that they do not have any known allergies to any of the components of the vaccines. [↑](#footnote-ref-2)